Due to poor air quality related to fires in California, the Academy’s San Francisco offices will be closed Friday, Nov. 16. Member support staff will not be available by phone and responses to emails may be delayed.

  • Allergan, Inc., and Medytox, Inc.
    Comprehensive Ophthalmology, Neuro-Ophthalmology/Orbit

    Allergan and Medytox have closed a previously announced licensing agreement for the development and commercialization of neurotoxin product candidates in development.

    Under the terms of the agreement, Allergan will pay Medytox an upfront cash payment of $65 million, and Medytox has granted Allergan exclusive rights worldwide outside of Korea to develop and, if approved, commercialize certain neurotoxin product candidates currently in development, including a potential liquid-injectable product.

    Allergan has also agreed to make additional contingent payments, including up to an aggregate of $116.5 million upon achieving certain development milestones, up to an aggregate of $180.5 million upon achieving certain commercialization milestones, and royalties on product sales.